Diabetes
🇺🇸 FDA Page 2FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Unlock global diabetes market insights. Get critical pharma intelligence on R&D, regulatory approvals, and investment opportunities for diabetes treatments.
Showing 13–24 of 29 articles
Mounjaro FDA Approval: Eli Lilly's Tirzepatide Milestone
Inflation Reduction Act Drug Pricing: Impact on FDA Negotiations & Innovation 2026
SURPASS-CVOT Trial Results: Implications for Mounjaro's Cardiovascular Safety and FDA Labeling
GLP-1 Eating Disorder Risk: What You Need to Know
Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial
Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug
COFEPRIS Drug Approvals 2026: Key Trends and Healthcare Implications
Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes
Lupin Launches Generic Dapagliflozin-Metformin XR Tablets in US as Xigduo XR Alternative
FDA Approves Sanofi's Tzield for Children Age 1+ to Delay Type 1 Diabetes Onset
Inflation Reduction Act pharmaceutical impact: What You Need to Know
Saudi Arabian Pharmaceutical Market: Impact of SFDA's Accelerated Drug Approvals